文献速递胸部肿瘤放疗放疗物理与技术

放射剂量对免疫细胞(EDIC)对小细胞肺癌肿瘤结局的影响

Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC).
PubMed 文献 · Radiother Oncol · 2025-09-06

该回顾性研究分析2006至2020年间在德国三级癌症中心接受胸部放疗的220例小细胞肺癌(SCLC)患者,计算有效免疫细胞剂量(EDIC)。在局限期SCLC中,较高EDIC(>4.9 Gy)与更短的总生存、无进展生存和远处无转移生存独立相关,但在广泛期SCLC中无预后影响。

要点

  • 局限期SCLC中,EDIC>4.9 Gy与更短OS、PFS和DMFS独立相关。
  • 广泛期SCLC中,EDIC未见预后影响。
  • 局限期SCLC其他独立预后因素包括预防性颅脑照射和每日两次分割放疗。

核心结论

  • 较高EDIC是局限期SCLC的独立负面预后因素,与更短OS、PFS和DMFS相关,但在广泛期SCLC中无预后相关性。

研究设计与样本

  • 回顾性分析2006至2020年间在德国三级癌症中心接受胸部放疗的220例SCLC患者,使用Jin等模型从治疗计划计算EDIC。

主要发现

  • 中位OS为17.7个月(Q1-Q3:11.6-38.8,95%CI:16.0-19.3)。
  • 局限期SCLC中,EDIC>4.9 Gy与更短OS独立相关(HR 1.62,p=0.011)。
  • 局限期SCLC中,EDIC>4.9 Gy与更短PFS独立相关(HR 1.57,p=0.037)。
  • 局限期SCLC中,EDIC>4.9 Gy与更短DMFS独立相关(HR 1.72,p=0.017),但与LPFS无关(p=0.308)。
  • 局限期SCLC其他独立预后因素包括预防性颅脑照射(HR 0.43,p<0.001)和每日两次分割放疗(HR 0.41,p=0.002)。

关键数值与推荐

  • 局限期SCLC中EDIC阈值4.9 Gy,高于此值与更短OS、PFS、DMFS独立相关。
  • 预防性颅脑照射在局限期SCLC中HR 0.43(p<0.001)。
  • 每日两次分割放疗在局限期SCLC中HR 0.41(p=0.002)。

临床怎么用

  • 在局限期SCLC放疗计划中可考虑计算EDIC以评估免疫抑制风险。
  • 随着免疫治疗进入局限期SCLC治疗,应发展保护免疫的放疗策略以优化患者结局。

局限性

  • 回顾性研究设计。
  • 单中心数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy (RT) is an essential part of small-cell lung cancer (SCLC) treatment. It can however deplete circulating lymphocytes, impairing systemic immune surveillance and potentially reducing the efficacy of immune checkpoint inhibitors (ICIs). The Effective Dose to Immune Cells (EDIC) quantifies RT-induced immune suppression and has been linked to survival in non-small cell lung cancer (NSCLC), but its prognostic significance in SCLC remains unclear. MATERIALS AND METHODS: We retrospectively analyzed 220 patients with SCLC who received thoracic RT at a German tertiary cancer center between 2006 and 2020. EDIC was calculated from treatment plans using the model developed by Jin et al., which approximates the dose to circulating immune cells based on the dose to circulating blood. The primary endpoint was overall survival (OS), secondary endpoints were progression-free survival (PFS), distant metastasis-free survival (DMFS), and local progression-free survival (LPFS). Multivariable Cox regression identified independent prognostic factors. RESULTS: The median OS was 17.7 months (Q1-Q3: 11.6-38.8, 95 % CI: 16.0-19.3). In LD-SCLC, higher EDIC (> 4.9 Gy) was independently associated with shorter OS (HR 1.62, p = 0.011), PFS (HR 1.57, p = 0.037), and DMFS (HR 1.72, p = 0.017), but not LPFS (p = 0.308). In contrast, EDIC showed no prognostic impact in ED-SCLC. Other independent prognostic factors in LD-SCLC included prophylactic cranial irradiation (HR 0.43, p < 0.001) and bi-daily fractionation (HR 0.41, p = 0.002). CONCLUSION: Higher EDIC is an independent negative prognostic factor in LD-SCLC, correlating with shorter OS, PFS, and DMFS, but had no prognostic relevance in ED-SCLC in this analysis. As immunotherapy becomes part of LD-SCLC treatment, immune-preserving RT strategies should be developed to optimize patient outcomes.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Penzl HS, Ziegler DA, Schirmer MA, et al. Impact of radiation dose on immune cells (EDIC) on oncologic outcome in small cell lung cancer (SCLC). Radiother Oncol. 2025. PMID: 40921331. doi:10.1016/j.radonc.2025.111122

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。